2009年3月印度制药行业研究报告

是 否 +2 论坛币

k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群

赵安豆老师微信：zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

立即领取

感谢您参与论坛问题回答

经管之家送您两个论坛币！

+2 论坛币

【出版时间及名称】：2009年3月印度制药行业研究报告
        【作者】：IIFL 证券
        【文件格式】：PDF
        【页数】：94
        【目录或简介】：
Contents
Generics: multiple tailwinds ...................................................................... 1
Core generics the way to go; give a break to alternative themes.................... 2
More growth drivers ahead ..................................................................... 14
Our top picks........................................................................................ 32
Companies
Biocon (BUY) ........................................................................................ 39
Cipla (BUY) .......................................................................................... 43
Dishman Pharma (ADD) ......................................................................... 49
Dr Reddy’s Lab (BUY) ............................................................................ 53
Glaxo SmithKline Pharma (ADD) ............................................................. 57
Glenmark Pharma (SELL) ....................................................................... 61
Jubilant Organosys (REDUCE) ................................................................. 65
Opto Circuits (BUY) ............................................................................... 69
Ranbaxy (REDUCE) ............................................................................... 73
Sun Pharma (BUY) ................................................................................ 77
Appendix 1: FDA approvals under PEPFAR ................................................ 89
Inserts (inside back cover)
Diabetes: Mother of all lifestyle diseases
Coronary artery disease (CAD): Protect your pulse

扫码加我 拉你入群

请注明：姓名-公司-职位

以便审核进群资格，未注明则拒绝

分享0 收藏1 回帖

关键词：行业研究报告 制药行业 研究报告 行业研究 Alternative 研究报告 行业 印度

谢谢，辛苦了